Medical/Pharmaceuticals

SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats

* Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. * SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza. * "We will promote global public health and grow...

2025-05-06 20:00 2551

"Gedeon Richter House of Hope" opens its doors to support 300 women annually in Africa-Bamako

BUDAPEST, Hungary, May 6, 2025 /PRNewswire/ -- A center providing healthcare and educational support as well as shelter for vulnerable women has beenbuilt in Bamako, the capital of Mali, with financial assistance from Gedeon Richter. As one of the world's leading manufacturers of women's healthca...

2025-05-06 19:01 2196

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (E...

2025-05-06 16:55 2597

Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy

–  Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related d...

2025-05-06 13:00 2689

Asia Pacific Initiative on Reproduction (ASPIRE) 2025 Congress: Fatherhood role models a new focus in filling the gap between actual and desired family sizes

SINGAPORE, May 6, 2025 /PRNewswire/ -- Presenting fatherhood as cool, admirable and masculine is likely to headline a new fertility rebound initiative across theAsia Pacific region as birth rates continue to fall at alarming levels. Renowned reproductive endocrinologist Emeritus Professor Domin...

2025-05-06 12:45 2355

Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform

GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform,...

2025-05-06 10:01 2085

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025

SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2025-05-06 08:00 2894

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagoni...

2025-05-06 07:00 2042

INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral Preparedness

Global antiviral R&D is slowing when the world can least afford it,  new analysis shows CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ -- The INTREPID Alliance today released the fourth edition of itsAntiviral Clinical and Preclinical Development Landscape, a comprehensive analysis of the global pi...

2025-05-06 02:16 1902

Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma

Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ -- Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieu...

2025-05-05 21:00 2103

Revolutionary test for male infertility can be a game changer for couples striving to conceive

SINGAPORE, May 5, 2025 /PRNewswire/ -- A simple, but revolutionary test has been developed to help unravel the mystery of infertility among men who display normal semen parameters. Infertility affects an estimated one in every six couples worldwide with male factor prevalent in about half of t...

2025-05-05 09:00 2587

IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance

SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial inthe United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS07...

2025-05-04 14:48 3142

A future of reproductive medicine where humanity and trust sit in harmony with spectacular advances in artificial intelligence

SINGAPORE, May 3, 2025 /PRNewswire/ -- Artificial intelligence, or AI, is transforming our lives in dynamic and challenging ways, including the ability to create life. In assisted reproduction, AI and automation tools have taken fertility specialists to new frontiers in precision, efficiency a...

2025-05-03 09:47 4303

Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation

* Seegene previews a concept video of CURECATM at ESCMID Global 2025, ahead of its anticipated debut in July * With a fully modular design, CURECATM introduces a bold vision for automating pre-treatment across diverse PCR specimen types * Developed for future integration into unattended work...

2025-05-02 21:00 4643

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the14th International Bone Morphogenetic Protein (BMP) Conference, taking ...

2025-05-02 19:30 2859

CPHI South East Asia 2025: Your gateway to ASEAN's expanding pharmaceutical landscape

KUALA LUMPUR, Malaysia, May 2, 2025 /PRNewswire/ -- As Southeast Asia's pharmaceutical industry rapidly evolves—driven by regulatory harmonization, innovation, and growing healthcare demand—CPHI South East Asia 2025 provides a vital platform to connect with regional stakeholders, showcase breakth...

2025-05-02 19:25 4453

Siemens Healthineers unveils MAMMOMAT B.brilliant, a revolutionary mammography system in Indonesia

SURABAYA, Indonesia, May 2, 2025 /PRNewswire/ -- Breast cancer remains one of the leading health concerns in Indonesia and ranks as the third deadliest cancer after lung and liver cancer. According to the Global Cancer Observatory, breast cancer accounts for 66,271 new cases (16.2%) out of a tota...

2025-05-02 16:08 3182

How latest genetic data on fertility may be an indicator of chronic disease onset and longevity

SINGAPORE, May 2, 2025 /PRNewswire/ -- Latest population studies have cast new light on genetic influences on women's reproductive lifespans and possible markers for the onset of chronic diseases. Evidence is growing that conditions such as cardiovascular disease, type 2 diabetes, rheumatoid a...

2025-05-02 15:59 3791

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.

AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficac...

2025-05-02 10:42 3006

HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion

SINGAPORE, May 2, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9 million inves...

2025-05-02 10:00 2867
1 ... 91929394959697 ... 646

Week's Top Stories